<VariationArchive RecordType="classified" VariationID="830311" VariationName="GRCh37/hg19 15q23(chr15:72662932-72670877)" VariationType="copy number loss" Accession="VCV000830311" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-19" DateCreated="2020-04-06" MostRecentSubmission="2020-04-06">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="818710" VariationID="830311">
      <GeneList>
        <Gene Symbol="HEXA" FullName="hexosaminidase subunit alpha" GeneID="3073" HGNC_ID="HGNC:4878" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>15q23</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="72340924" stop="72376014" display_start="72340924" display_stop="72376014" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="72635777" stop="72668519" display_start="72635777" display_stop="72668519" Strand="-" />
          </Location>
          <OMIM>606869</OMIM>
        </Gene>
        <Gene Symbol="HEXA-AS1" FullName="HEXA antisense RNA 1" GeneID="80072" HGNC_ID="HGNC:25810" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>15q23</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="72376113" stop="72378788" display_start="72376113" display_stop="72378788" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>GRCh37/hg19 15q23(chr15:72662932-72670877)</Name>
      <VariantType>copy number loss</VariantType>
      <Location>
        <CytogeneticLocation>15q23</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" innerStart="72662932" innerStop="72670877" display_start="72662932" display_stop="72670877" variantLength="7946" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.(?_72662932)_(72670877_?)del" Assembly="GRCh37">
            <Expression>NC_000015.9:g.(?_72662932)_(72670877_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="GRCh37/hg19 15q23(chr15:72662932-72670877) AND Tay-Sachs disease" Accession="RCV001030746" Version="2">
        <ClassifiedConditionList TraitSetID="1067">
          <ClassifiedCondition DB="MedGen" ID="C0039373">Tay-Sachs disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-12-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-12-04" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-06" MostRecentSubmission="2020-04-06">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">2824459</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3754980</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1067" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6027" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Tay-Sachs disease</ElementValue>
                <XRef ID="Tay+Sachs+disease/7008" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010100" DB="MONDO" />
                <XRef ID="111385000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hexosaminidase A Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM2 gangliosidosis, type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HexA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hexosaminidase alpha-subunit deficiency (variant B)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sphingolipidosis, Tay-Sachs</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TSD</ElementValue>
                <XRef Type="MIM" ID="272800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity. This, in turn, depends on the molecular characteristics and biological impact of the HEXA pathogenic variants. HEX A is necessary for degradation of GM2 ganglioside; without well-functioning enzymes, GM2 ganglioside builds up in the lysosomes of brain and nerve cells. The classic clinical phenotype is known as Tay-Sachs disease (TSD), characterized by progressive weakness, loss of motor skills beginning between ages three and six months, decreased visual attentiveness, and increased or exaggerated startle response with a cherry-red spot observable on the retina followed by developmental plateau and loss of skills after eight to ten months. Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years. Subacute juvenile TSD is associated with normal developmental milestones until age two years, when the emergence of abnormal gait or dysarthria is noted followed by loss of previously acquired skills and cognitive decline. Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration. Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis. Clinical variability even among affected members of the same family is observed in both the subacute juvenile and the late-onset TSD phenotypes.</Attribute>
                <XRef ID="NBK1218" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7737" />
                <XRef ID="7737" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301397</ID>
                <ID Source="BookShelf">NBK1218</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2018">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <XRef ID="845" DB="Orphanet" />
              <XRef ID="C0039373" DB="MedGen" />
              <XRef ID="MONDO:0010100" DB="MONDO" />
              <XRef Type="MIM" ID="272800" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2354271" SubmissionDate="2020-01-15" DateLastUpdated="2020-04-06" DateCreated="2020-04-06">
        <ClinVarSubmissionID localKey=":Chr.15_72662932_72670877_copy number loss|OMIM:272800" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001193816" DateUpdated="2020-04-06" DateCreated="2020-04-06" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-12-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">3754980</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2824459</ID>
          </Citation>
          <Comment>7.6kb del NM_000520.4(HEXA):c.-2564_253+5128delinsG is classified as pathogenic in the context of hexosaminidase A deficiency. Sources cited for classification include the following: PMID 3754980 and 2824459. Classification of 7.6kb del NM_000520.4(HEXA):c.-2564_253+5128delinsG is based on the following criteria: The variant is a large genomic, multi-exon, or single-exon deletion. This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Women's Health Autosomal Recessive and X-Linked Classification Criteria (2019)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/vlxza0ea/myriad_women_s_health_autosomal_recessive_and_x-linked_classification_criteria_2019_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HEXA" />
            <Gene Symbol="HEXA-AS1" />
          </GeneList>
          <VariantType>copy number loss</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="15" innerStart="72662932" innerStop="72670877" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="272800" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6849778</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2354271" TraitType="Disease" MappingType="XRef" MappingValue="272800" MappingRef="OMIM">
        <MedGen CUI="C0039373" Name="Tay-Sachs disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

